The influence of finasteride on the development of prostate cancer.
4/5 보강
TL;DR
Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
📑 코퍼스 인용 관계
· 인용됨 41
📑 인용한 논문 (6) ▾
- SRD5A2 and emerging therapies in androgen-driven disorders. Nature reviews. Urology · 2026
- Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics an… BJU international · 2026
- Artificial intelligence-derived transition zone PSA density as a triage tool to reduce unn… Insights into imaging · 2026
- Management of Lower Urinary Tract Symptoms in Patients on Active Surveillance for Prostate… Current urology reports · 2026
- Multi-institutional evaluation of prostate specific antigen dynamics after simple prostate… World journal of urology · 2026
- Does prior TURP affect mpMRI findings or tumor grade in patients with prostate cancer? World journal of urology · 2026
연도별 인용 (2012–2026) · 합계 1,125
OpenAlex 토픽 ·
Prostate Cancer Diagnosis and Treatment
Prostate Cancer Treatment and Research
Prostate Cancer Diagnosis and Treatment
Abstract 🌐 Abstract
[BACKGROUND] Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer.
[METHODS] In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal. It was anticipated that 60 percent of participants would have prostate cancer diagnosed during the study or would undergo biopsy at the end of the study. The primary end point was the prevalence of prostate cancer during the seven years of the study.
[RESULTS] Prostate cancer was detected in 803 of the 4368 men in the finasteride group who had data for the final analysis (18.4 percent) and 1147 of the 4692 men in the placebo group who had such data (24.4 percent), for a 24.8 percent reduction in prevalence over the seven-year period (95 percent confidence interval, 18.6 to 30.6 percent; P<0.001). Tumors of Gleason grade 7, 8, 9, or 10 were more common in the finasteride group (280 of 757 tumors [37.0 percent], or 6.4 percent of the 4368 men included in the final analysis) than in the placebo group (237 of 1068 tumors [22.2 percent], P<0.001 for the comparison between groups; or 5.1 percent of the 4692 men included in the final analysis, P=0.005 for the comparison between groups). Sexual side effects were more common in finasteride-treated men, whereas urinary symptoms were more common in men receiving placebo.
[CONCLUSIONS] Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
[METHODS] In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal. It was anticipated that 60 percent of participants would have prostate cancer diagnosed during the study or would undergo biopsy at the end of the study. The primary end point was the prevalence of prostate cancer during the seven years of the study.
[RESULTS] Prostate cancer was detected in 803 of the 4368 men in the finasteride group who had data for the final analysis (18.4 percent) and 1147 of the 4692 men in the placebo group who had such data (24.4 percent), for a 24.8 percent reduction in prevalence over the seven-year period (95 percent confidence interval, 18.6 to 30.6 percent; P<0.001). Tumors of Gleason grade 7, 8, 9, or 10 were more common in the finasteride group (280 of 757 tumors [37.0 percent], or 6.4 percent of the 4368 men included in the final analysis) than in the placebo group (237 of 1068 tumors [22.2 percent], P<0.001 for the comparison between groups; or 5.1 percent of the 4692 men included in the final analysis, P=0.005 for the comparison between groups). Sexual side effects were more common in finasteride-treated men, whereas urinary symptoms were more common in men receiving placebo.
[CONCLUSIONS] Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
- p-value P<0.001
Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of
APA 7
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., Carlin, S. M., Ryan, A., Szczepanek, C. M., Crowley, J. J., & Coltman, C. A. (2003). The influence of finasteride on the development of prostate cancer.. The New England journal of medicine, 349(3), 215-24. https://doi.org/10.1056/NEJMoa030660
Vancouver
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. New Engl. jour. medi.. 2003;349(3):215-24. doi:10.1056/NEJMoa030660
AMA 11
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. New Engl. jour. medi.. 2003;349(3):215-24. doi:10.1056/NEJMoa030660
Chicago
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., and .... 2003. "The influence of finasteride on the development of prostate cancer." The New England journal of medicine 349 (3): 215-24. https://doi.org/10.1056/NEJMoa030660
MLA 9
Thompson, I. M., et al. "The influence of finasteride on the development of prostate cancer." The New England journal of medicine, vol. 349, no. 3, 2003, pp. 215-24. doi:10.1056/NEJMoa030660.
PMID
12824459 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 20
- Androgenetic Alopecia: An Update of Treatment Options.
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic …
- Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
- Hair restoration surgery: challenges and solutions.
- Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgene…
- A Comment on the Post-Finasteride Syndrome.
- Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
- Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries…
- Association of finasteride with prostate cancer: A systematic review and meta-analysis.
- Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Ca…
- Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Tri…
- Protective effects of finasteride against testosterone-induced calcium oxalate crystallization and c…
- The post-finasteride syndrome: possible etiological mechanisms and symptoms.
- Post-finasteride syndrome - a true clinical entity?
- Development and Skin Penetration Pathway Evaluation Using Confocal Laser Scanning Microscopy of Micr…
- The Interplay between Finasteride-Induced Androgen Imbalance, Endoplasmic Reticulum Stress, Oxidativ…
- Methylated CpG dinucleotides in the 5-α reductase 2 gene may explain finasteride resistance in benig…
- Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cance…
- The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor,…
- The intriguing role of fibroblasts and in the chemopreventive and therapeutic effect of finasteride…
같은 제1저자의 인용 많은 논문 (5)
- Long-term survival of participants in the prostate cancer prevention trial.
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
- Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
- Chemoprevention of prostate cancer.
- Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.